A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer. - Wakelee, Heather; Gettinger, Scott; Engelman, Jeffrey; Jänne, Pasi; West, Howard; Subramaniam, Deepa; Leach, Joseph; Wax, Michael; Yaron, Yifah; Miles, Dale; Lara, Primo; Wakelee, Heather A; et al. (Cancer Chemotherapy & Pharmacology, 2017)